BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29958926)

  • 21. Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology.
    McCart Reed AE; Kutasovic JR; Nones K; Saunus JM; Da Silva L; Newell F; Kazakoff S; Melville L; Jayanthan J; Vargas AC; Reid LE; Beesley J; Chen XQ; Patch AM; Clouston D; Porter A; Evans E; Pearson JV; Chenevix-Trench G; Cummings MC; Waddell N; Lakhani SR; Simpson PT
    J Pathol; 2018 Apr; 244(4):460-468. PubMed ID: 29344954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
    van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
    Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histopathological features of breast cancer in carriers of ATM gene variants.
    Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
    Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
    J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
    Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
    Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
    Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline Genetic Features of Young Individuals With Colorectal Cancer.
    Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
    Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    van der Groep P; van Diest PJ; Smolders YH; Ausems MG; van der Luijt RB; Menko FH; Bart J; de Vries EG; van der Wall E
    PLoS One; 2013; 8(2):e56055. PubMed ID: 23409121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expectations of Surveillance for Non-BRCA Gene Mutation Carriers at Increased Risk for Breast Cancer.
    Caskey R; Singletary B; Ayre K; Parker C; Krontiras H; Lancaster RB
    J Surg Res; 2020 Dec; 256():267-271. PubMed ID: 32712440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer.
    Mangia A; Tommasi S; Bruno M; Malfettone A; D'Amico C; Zito FA; Paradiso A; Simone G
    Oncol Rep; 2010 Jun; 23(6):1641-5. PubMed ID: 20428820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
    Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
    Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.